India · Delayed Price · Currency is INR Verve Therapeutics Statistics
Total Valuation
BOM:543308 has a market cap or net worth of INR 284.62 billion. The enterprise value is 311.98 billion.
| Market Cap | 284.62B |
| Enterprise Value | 311.98B |
Important Dates
The last earnings date was Thursday, August 7, 2025.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 400.14M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 207.70M |
Valuation Ratios
The trailing PE ratio is 75.60 and the forward PE ratio is 58.74.
| PE Ratio | 75.60 |
| Forward PE | 58.74 |
| PS Ratio | 8.84 |
| PB Ratio | 11.77 |
| P/TBV Ratio | 16.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 82.86 |
| EV / Sales | 9.69 |
| EV / EBITDA | 39.30 |
| EV / EBIT | 51.61 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 1.06 |
| Debt / EBITDA | 3.22 |
| Debt / FCF | n/a |
| Interest Coverage | 5.76 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 8.97% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 6.11M |
| Profits Per Employee | 715,236 |
| Employee Count | 5,013 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BOM:543308 has paid 1.40 billion in taxes.
| Income Tax | 1.40B |
| Effective Tax Rate | 25.72% |
Stock Price Statistics
The stock price has increased by +66.05% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +66.05% |
| 50-Day Moving Average | 700.93 |
| 200-Day Moving Average | 626.49 |
| Relative Strength Index (RSI) | 43.49 |
| Average Volume (20 Days) | 119,034 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BOM:543308 had revenue of INR 32.18 billion and earned 3.77 billion in profits. Earnings per share was 9.41.
| Revenue | 32.18B |
| Gross Profit | 20.18B |
| Operating Income | 6.05B |
| Pretax Income | 5.45B |
| Net Income | 3.77B |
| EBITDA | 7.94B |
| EBIT | 6.05B |
| Earnings Per Share (EPS) | 9.41 |
Balance Sheet
The company has 1.02 billion in cash and 25.57 billion in debt, giving a net cash position of -24.55 billion.
| Cash & Cash Equivalents | 1.02B |
| Total Debt | 25.57B |
| Net Cash | -24.55B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 24.19B |
| Book Value Per Share | 53.34 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 62.71%, with operating and profit margins of 18.78% and 11.70%.
| Gross Margin | 62.71% |
| Operating Margin | 18.78% |
| Pretax Margin | 16.93% |
| Profit Margin | 11.70% |
| EBITDA Margin | 24.67% |
| EBIT Margin | 18.78% |
| FCF Margin | n/a |
Dividends & Yields
BOM:543308 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.01% |
| Shareholder Yield | n/a |
| Earnings Yield | 1.32% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 13, 2024. It was a forward split with a ratio of 5.
| Last Split Date | Sep 13, 2024 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |